Latest

Understand the 1-mg low-dose dexamethasone suppression test, the common cortisol cutoff of 1.8 mcg/dL, causes of nonsuppression, and the follow-up used for Cushing screening.

Low-Dose Dexamethasone Suppression Test: Cushing Syndrome Screening and Results

Learn how an 8–9 a.m. cortisol test screens for adrenal insufficiency, what low and intermediate results mean, how ACTH helps identify the cause, and when stimulation testing is needed.

Morning Cortisol Test: Low Levels, Adrenal Insufficiency, and Results

Learn how a pheochromocytoma and paraganglioma panel uses plasma or urine metanephrines, normetanephrine, catecholamines, and controlled collection to interpret abnormal results.

Pheochromocytoma and Paraganglioma Test Panel: Metanephrines, Normetanephrine, Catecholamines, and Results

Learn what plasma epinephrine, norepinephrine, and dopamine results mean, why collection posture matters, common causes of high values, and when metanephrine testing is preferred.

Plasma Catecholamines Test: Epinephrine, Norepinephrine, Dopamine, and Results

Learn how plasma free metanephrine and normetanephrine testing screens for pheochromocytoma and paraganglioma, why supine rest matters, and how high or borderline results are evaluated.

Plasma Free Metanephrines Test: Pheochromocytoma and Paraganglioma Screening, High Levels, and Results

Learn what a high plasma normetanephrine result means, why supine rest matters, common false-positive causes, when clonidine testing is used, and how PPGL evaluation proceeds.

Plasma Normetanephrine Test: High Levels, Pheochromocytoma Screening, and Results

Diagnostics

Home Diagnostics Page 4

Understand HTR2A antidepressant testing, common variants, evidence for response and side effects, report limitations, and why current guidelines recommend no HTR2A-based action.

HTR2A Genetic Test: Antidepressant Response, Side Effects, and Results

Understand what an IFNL3 or IL28B genetic test shows, how CC, CT, and TT results were used in older hepatitis C care, and why modern DAA treatment relies on other clinical tests.

IFNL3 Genetic Test: Hepatitis C Treatment Response and Results

Learn how NAT2 testing identifies slow, intermediate, or rapid isoniazid acetylator status, what the result may mean for TB treatment and toxicity, and why specialist monitoring remains essential.

NAT2 Genetic Test: Isoniazid Metabolism, Slow Acetylator Status, and Results

Understand NUDT15 test results, thiopurine leukopenia risk, and how normal, intermediate, or poor metabolizer status can affect mercaptopurine, azathioprine, and thioguanine starting doses.

NUDT15 Genetic Test: Thiopurine Toxicity, Leukopenia Risk, and Results

Understand what an OPRM1 genetic test shows, how AA, AG, and GG results relate to opioid response, why dosing guidance is limited, and how to use results safely.

OPRM1 Genetic Test: Opioid Response, Pain Treatment, and Results

Learn how pain medication pharmacogenetic testing uses CYP2D6, OPRM1, and related genes to clarify opioid response, codeine and tramadol risks, test results, and treatment choices.

Pain Medication Pharmacogenetic Test: Opioids, CYP2D6, OPRM1, and Results

Understand what a pharmacogenetic panel test measures, which medication-response genes may be actionable, how results are interpreted, and how panels can guide safer prescribing.

Pharmacogenetic Panel Test: Medication Response, Gene Variants, and Results

Learn what psychiatric pharmacogenetic testing can and cannot predict for antidepressants and antipsychotics, including CYP2D6, CYP2C19, SLC6A4, results, limits, and safe treatment use.

Psychiatric Pharmacogenetic Test: Antidepressants, Antipsychotics, Genes, and Results

Learn how RYR1 genetic testing evaluates malignant hyperthermia susceptibility, what positive, negative, and uncertain results mean, and how to plan safe trigger-free anesthesia.

RYR1 Genetic Test: Malignant Hyperthermia Risk and Anesthesia Results

Understand SLC6A4 genetic testing, 5-HTTLPR and rs25531 results, the evidence on SSRI response, why guidelines do not recommend stand-alone prescribing changes, and how to use findings safely.

SLC6A4 Genetic Test: Antidepressant Response, Serotonin Transporter, and Results

Learn what an SLCO1B1 genetic test reveals about simvastatin exposure and statin muscle-risk, how results are reported, and how clinicians may use them safely.

SLCO1B1 Genetic Test: Statin Muscle Risk, Simvastatin, and Results

Understand how a statin pharmacogenetic test uses SLCO1B1, ABCG2, and CYP2C9 results to assess muscle-risk and guide safer, effective statin choices.

Statin Pharmacogenetic Test: SLCO1B1, Muscle Pain Risk, and Results

Learn how CYP3A5 pharmacogenetic testing can guide an initial tacrolimus dose after transplant, how results are interpreted, and why trough monitoring remains essential.

Tacrolimus Pharmacogenetic Test: CYP3A5, Dose, Transplant, and Results

Learn how TPMT and NUDT15 pharmacogenetic testing predicts thiopurine toxicity risk, guides safer starting doses, and works with ongoing blood-count monitoring.

Thiopurine Pharmacogenetic Test: TPMT, NUDT15, Toxicity Risk, and Results

Learn how a TPMT genetic test predicts azathioprine and mercaptopurine toxicity risk, how metabolizer results guide starting doses, and why NUDT15 and blood monitoring still matter.

TPMT Genetic Test: Thiopurine Toxicity, Azathioprine, Mercaptopurine, and Results

Learn how UGT1A1 testing can predict irinotecan toxicity risk, support a Gilbert syndrome diagnosis, and clarify the meaning of *28, *6, and metabolizer results.

UGT1A1 Genetic Test: Irinotecan Toxicity, Gilbert Syndrome, and Results

Learn how a VKORC1 genetic test predicts warfarin sensitivity, what G/G, G/A, and A/A results mean, and why dosing still requires CYP2C9 data and INR monitoring.

VKORC1 Genetic Test: Warfarin Sensitivity, Dose, and Results

Understand how a warfarin pharmacogenetic test uses CYP2C9, VKORC1, CYP4F2, and ancestry-aware results to estimate dose while INR monitoring guides safe treatment.

Warfarin Pharmacogenetic Test: CYP2C9, VKORC1, CYP4F2, Dose, and Results

Understand Alzheimer disease genetic testing for APOE, APP, PSEN1, and PSEN2, including who should test, result meanings, family risk, and treatment safety.

Alzheimer Disease Genetic Test: APOE, APP, PSEN1, PSEN2, and Results

Learn how ALS genetic testing evaluates C9orf72, SOD1, TARDBP, FUS, and other genes, what results mean, and how findings can affect treatment and family risk.

Amyotrophic Lateral Sclerosis (ALS) Genetic Test: C9orf72, SOD1, TARDBP, and Results

1...345...57 Page 4 of 57